Loading
Orthopediatrics Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 25 Aug 2025.
Orthopediatrics Corp: what insiders have been doing
Orthopediatrics Corp, classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). From 18 October 2025 to 18 October 2026, the disclosure feed for Orthopediatrics Corp logged 19 filings by 11 insiders.
Only sales appear on the open market, 8 sales in all totalling €13.7M, filed by 4 insiders. One trade stands out by size: a sale of €6.5M from Pritzker Jennifer N., disclosed on 1 September 2026, or 1.3% of market capitalisation.
The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
Compared with its exchange (5,814 companies, median 19 filings), a count of 19 filings is typical. Looking back to 2021, when coverage begins, insiders filed 6 purchases and 51 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 236.3 m USD and net income of -39.6 m USD.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
163
Thresholds
n/a
Buy Volume
€325,404
6 ops. · all time
Sell Volume
€20M
51 ops. · all time
Who traded when
BuySaleDavid R. Pelizzon7 sales
Jennifer N. Pritzker7 sales
Squadron Capital LLC7 sales
David R. Bailey1 sale
Hite Fred1 buy
Since the insiders bought
- +8.6%Entry US$22.12 · Close at T+365 US$24.03
- +12.5%Entry US$41.10 · Close at T+365 US$46.22
- -29.2%Entry US$56.77 · Close at T+365 US$40.20
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 19,427 of 24,148 companies
30.6
score / 100
Value23
Quality38
FCF yld-2.8%
Earn yld-6.9%
EV/EBITDA·
ROE-11%
Gross mgn73%
Net mgn-17%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$22.25
Analyst consensus
9 analysts1.56/5
US$22.00Target US$27.22(+22%)US$35.00
Income statement
RevenueUS$236.3M
Gross profitUS$172.7M73% margin
EBITDA-US$7.9M-3% margin
Net income-US$39.6M-15.7% margin
Valuation
PER (forward)-31.3x
P/Book1.7x
Beta0.99
Balance sheet & cash
Market capUS$580.9M
Total debtUS$100M
Free Cash Flow-US$16M
Debt / Equity32%
Profitability & ownership
ROE-11.4%
ROA-2.8%
% insiders29.7%
% institutions65.7%
Last declaration on 11 September 2026
Declarations163 total
▼
Same trade as the filing by David R. Pelizzon, counted once · View ↗
302,369 shares@ US$21.011.07% mcap43.4% of flowCommon StockSEC:0001193125-26-388664:0
▼
Same trade as the filing by David R. Pelizzon, counted once · View ↗
302,369 shares@ US$21.011.07% mcap43.4% of flowCommon StockSEC:0001193125-26-388667:0
302,369 shares@ US$21.011.07% mcap43.4% of flowCommon StockSEC:0001425450-26-000087:0
22,500 shares@ US$23.350.089% mcap3.6% of flowCommon StockSEC:0001193125-26-383746:0
▼
Same trade as the filing by Jennifer N. Pritzker, counted once · View ↗
22,500 shares@ US$23.350.089% mcap3.6% of flowCommon StockSEC:0001193125-26-383761:0
▼
Same trade as the filing by Jennifer N. Pritzker, counted once · View ↗
22,500 shares@ US$23.350.089% mcap3.6% of flowCommon StockSEC:0001425450-26-000085:0
326,700 shares@ US$23.041.26% mcap51.4% of flowCommon StockSEC:0001193125-26-378877:0
▼
Same trade as the filing by Jennifer N. Pritzker, counted once · View ↗
326,700 shares@ US$23.041.26% mcap51.4% of flowCommon StockSEC:0001425450-26-000083:0
▼
Same trade as the filing by Jennifer N. Pritzker, counted once · View ↗
326,700 shares@ US$23.041.26% mcap51.4% of flowCommon StockSEC:0001193125-26-378892:0
10,131 shares@ US$23.100.039% mcap1.6% of flowCommon StockSEC:0001193125-26-378877:1
▼
Same trade as the filing by Jennifer N. Pritzker, counted once · View ↗
10,131 shares@ US$23.100.039% mcap1.6% of flowCommon StockSEC:0001193125-26-378892:1
▼
Same trade as the filing by Jennifer N. Pritzker, counted once · View ↗
10,131 shares@ US$23.100.039% mcap1.6% of flowCommon StockSEC:0001425450-26-000083:1
▼
Same trade as the filing by Squadron Capital LLC, counted once · View ↗
16,300 shares@ US$24.740.067% mcap40.4% of flowCommon StockSEC:0001425450-26-000081:1
4,000 shares@ US$25.750.017% mcap10.9% of flowCommon StockSEC:0001193125-26-369063:0
16,300 shares@ US$24.740.067% mcap42.7% of flowCommon StockSEC:0001193125-26-369063:1
18,000 shares@ US$24.280.072% mcap46.3% of flowCommon StockSEC:0001193125-26-369063:2
▼
Same trade as the filing by Squadron Capital LLC, counted once · View ↗
4,000 shares@ US$25.750.017% mcap9.2% of flowCommon StockSEC:0001193125-26-369065:0
▼
Same trade as the filing by Squadron Capital LLC, counted once · View ↗
16,300 shares@ US$24.740.067% mcap36.2% of flowCommon StockSEC:0001193125-26-369065:1
▼
Same trade as the filing by Squadron Capital LLC, counted once · View ↗
18,000 shares@ US$24.280.072% mcap39.2% of flowCommon StockSEC:0001193125-26-369065:2
▼
Same trade as the filing by Squadron Capital LLC, counted once · View ↗
4,000 shares@ US$25.750.017% mcap10.3% of flowCommon StockSEC:0001425450-26-000081:0
▼
Same trade as the filing by Squadron Capital LLC, counted once · View ↗
18,000 shares@ US$24.280.072% mcap43.7% of flowCommon StockSEC:0001425450-26-000081:2
700,000 shares@ US$26.233.03% mcap100.0% of flowCommon StockSEC144:0001425450-26-000079
119,140 sharesCommon StockSEC:0001425450-26-000056:0
11,436 sharesCommon StockSEC:0001425450-26-000052:0
11,436 sharesCommon StockSEC:0001425450-26-000059:0
25 of 163 declarations
About Orthopediatrics Corp
OrthoPediatrics Corp. (ticker: KIDS) is a U.S.-based medical device company listed on the Nasdaq, and its strategic identity is unusually focused: it is devoted exclusively to pediatric orthopedics. Headquartered in Warsaw, Indiana, United States, the company was founded in 2006 with the goal of addressing an underserved niche within orthopedics—devices and systems designed specifically for children and adolescents rather than scaled-down adult products. That focus is a key competitive advantage versus larger, more diversified medtech peers. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1425450/000142545026000013/0001425450-26-000013-index.htm?utm_source=openai))
The company markets nearly 90 surgical and bracing systems spanning three of the largest pediatric orthopedic categories: trauma and deformity, scoliosis, and sports medicine/other procedures. Its portfolio includes implants, instruments, and procedure-specific systems used by pediatric orthopedic surgeons, alongside an expanding specialty bracing business. Recent acquisitions such as Boston Orthotics & Prosthetics and MD Orthopaedics have broadened the non-operative side of the platform and deepened the company’s ability to serve patients across the treatment continuum, including clubfoot and other bracing indications. ([ir.orthopediatrics.com](https://ir.orthopediatrics.com/news-releases/news-release-details/orthopediatrics-corp-reports-fourth-quarter-and-full-year-2025?utm_source=openai))
Read moreShow less
From a market-positioning standpoint, OrthoPediatrics benefits from its exclusive pediatric specialty model. Rather than competing broadly across adult orthopedics, it concentrates resources on surgeon education, product innovation, and relationships with pediatric hospitals and specialists. Management also emphasizes a global commercial footprint: products are sold in the United States and in more than 75 countries outside the U.S., giving the company geographic diversification while keeping its core operating base in the domestic market. ([ir.orthopediatrics.com](https://ir.orthopediatrics.com/news-releases/news-release-details/orthopediatrics-corp-reports-fourth-quarter-and-full-year-2025?utm_source=openai))
Recent business developments have been constructive. In 2025, the company expanded its Specialty Bracing Division into new territories and opened additional clinics, underscoring a push to build a more integrated pediatric care platform. It also announced a distribution partnership with MY01 to widen access to technology aimed at pediatric trauma patients. Financially, OrthoPediatrics reported strong momentum into 2026, including 13% year-over-year revenue growth in the first quarter of 2026 to $59.4 million and 15% full-year 2025 revenue growth to $236.3 million, while also highlighting improved cash generation. These updates point to a business that is still investing, but increasingly demonstrating operating leverage and commercial scale. ([ir.orthopediatrics.com](https://ir.orthopediatrics.com/news-releases/news-release-details/orthopediatrics-corp-announces-continued-expansion-specialty?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
